Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | APAF1 | O14727 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13168986 | 0.86 | CHRNB2 (0.39) | CHRNB2CHRNA4KDM4EMEN1APAF1 | |
| SCHEMBL8931361 | 0.74 | EPHX2 (0.35) | MEN1GAAKMT2A | |
| SCHEMBL29332787 | 0.74 | EPHX2 (0.35) | MEN1GAAKMT2A | |
| SCHEMBL21316477 | 0.74 | EPHX2 (0.35) | MEN1GAAKMT2A | |
| SCHEMBL13362026 | 0.73 | CHRNB4 (0.46) | CHRNB2CHRNA4MAPT | |
| SCHEMBL4586631 | 0.70 | EPHX2 (0.37) | CHRNB2CHRNA4MEN1GAAKMT2A | |
| SCHEMBL10066652 | 0.70 | FDPS (0.32) | CHRNB2CHRNA4 | |
| SCHEMBL5178587 | 0.70 | CHRNB2 (0.37) | CHRNB2CHRNA4MEN1GAAKMT2A | |
| SCHEMBL20850872 | 0.68 | DRD1 (0.43) | CHRNB2CHRNA4KDM4EMEN1GAA | |
| SCHEMBL24781668 | 0.67 | DRD1 (0.39) | CHRNB2CHRNA4KDM4EMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331344-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100113555-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113555-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | CHRNB2 1750/4885CHRNA4 2282/4885KDM4E 4235/4885 |
| US-20100331344-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | CHRNB2 1750/4885CHRNA4 2282/4885KDM4E 4235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.